EVO:NSD-Evotec SE ADR (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 5

Change

+0.54 (+12.11)%

Market Cap

USD 1.70B

Volume

0.28M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

-0.09 (-0.72%)

USD 15.08B
NBIX Neurocrine Biosciences Inc

-0.46 (-0.34%)

USD 12.97B
ITCI Intracellular Th

+1.24 (+1.48%)

USD 8.85B
LNTH Lantheus Holdings Inc

+0.29 (+0.32%)

USD 6.19B
ALKS Alkermes Plc

+0.15 (+0.51%)

USD 5.01B
ALVO Alvotech

+0.04 (+0.32%)

USD 3.47B
HCM HUTCHMED DRC

+0.05 (+0.35%)

USD 2.94B
AMPH Amphastar P

-0.85 (-2.17%)

USD 2.09B
SUPN Supernus Pharmaceuticals Inc

+0.01 (+0.03%)

USD 2.05B
DVAX Dynavax Technologies Corporati..

+0.01 (+0.08%)

USD 1.69B

ETFs Containing EVO

EXV9:XETRA iShares (DE) I - iShares .. 17.04 % 0.00 %

N/A

USD 0.10B
BETS:XETRA 6.59 % 0.00 %

N/A

N/A
ODDS Pacer BlueStar Digital En.. 6.21 % 0.00 %

+0.08 (+0.54%)

USD 1.05M
PCIG Litman Gregory Funds Trus.. 4.22 % 0.00 %

+0.05 (+0.54%)

USD 0.03B
DXW:CA Dynamic Active Internatio.. 4.05 % 0.00 %

-0.04 (0.54%)

CAD 0.02B
XWD1:LSE Xtrackers MSCI World Swap.. 1.75 % 0.00 %

+0.16 (+0.54%)

N/A
BJK VanEck Gaming ETF 0.00 % 0.66 %

-0.06 (0.54%)

N/A
EWD iShares MSCI Sweden ETF 0.00 % 0.53 %

+0.10 (+0.54%)

N/A
IESZ:LSE 0.00 % 0.00 %

N/A

N/A
OMXS:LSE iShares OMX Stockholm Cap.. 0.00 % 0.00 %

-2.13 (0.54%)

N/A
DXSN:F Xtrackers - ShortDAX Dail.. 0.00 % 0.00 %

N/A

N/A
DXSP:F Xtrackers - Euro Stoxx 50.. 0.00 % 0.00 %

N/A

N/A
EL4C:F Deka STOXX Europe Strong .. 0.00 % 0.00 %

N/A

N/A
EXV9:F iShares (DE) I - iShares .. 0.00 % 0.00 %

N/A

N/A
XDN0:F db x-trackers MSCI Nordic.. 0.00 % 0.00 %

N/A

USD 1.10B
EL4C:XETRA Deka STOXX Europe Strong .. 0.00 % 0.00 %

N/A

USD 0.29B
OM3X:XETRA iShares OMX Stockholm Cap.. 0.00 % 0.00 %

N/A

USD 1.31B
XDN0:XETRA db x-trackers MSCI Nordic.. 0.00 % 0.00 %

N/A

USD 1.03B
BETZ Roundhill Sports Betting .. 0.00 % 0.00 %

+0.05 (+0.54%)

USD 0.08B
XNZN:XETRA Xtrackers Nordic Net Zero.. 0.00 % 0.00 %

N/A

USD 0.20B
XDN0:SW Xtrackers MSCI Nordic UCI.. 0.00 % 0.00 %

N/A

USD 1.10B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.37% 25% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.37% 25% F 15% F
Trailing 12 Months  
Capital Gain -57.26% 23% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.26% 23% F 15% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -20.23% 23% F 12% F
Dividend Return -20.23% 23% F 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.76% 83% B 66% D+
Risk Adjusted Return -72.89% 17% F 9% A-
Market Capitalization 1.70B 87% B+ 77% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector